Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.
about
Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort studyMonte Carlo decision curve analysis using aggregate data.Acute kidney injury as an independent risk factor for unplanned 90-day hospital readmissions.Quantifying the impact of different approaches for handling continuous predictors on the performance of a prognostic model.Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort studyAn etiologic prediction model incorporating biomarkers to predict the bladder cancer risk associated with occupational exposure to aromatic amines: a pilot study.Open reduction and internal fixation of humeral shaft fractures versus conservative treatment with a functional brace: a study protocol of a randomised controlled trial embedded in a cohort.New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality: A Validation and Clinical Decision-making Study.Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas?Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis.Key steps and common pitfalls in developing and validating risk models.Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.Development and validation of QMortality risk prediction algorithm to estimate short term risk of death and assess frailty: cohort study.An exploration of mortality risk factors in non-severe pneumonia in children using clinical data from Kenya.Diagnostic test strategies in children at increased risk of inflammatory bowel disease in primary care.Anti-Mullerian Hormone-to-Testosterone Ratio is Predictive of Positive Sperm Retrieval in Men with Idiopathic Non-Obstructive Azoospermia.A systematic review of neonatal treatment intensity scores and their potential application in low-resource setting hospitals for predicting mortality, morbidity and estimating resource use.Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study.Decision curve analysis as a framework to estimate the potential value of screening or other decision-making aids.Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account.Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis.Power Doppler Ultrasonography and Shear Wave Elastography as Complementary Imaging Methods for Suspected Local Breast Cancer Recurrence.Sensible economies: Demand management in blood science laboratories.A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath.Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.Development and evaluating multimarker models for guiding treatment decisions.Cardiovascular disease prevention at the workplace: assessing the prognostic value of lifestyle risk factors and job-related conditions.Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control studyExternal validation of computed tomography decision rules for minor head injury: prospective, multicentre cohort study in the NetherlandsDecision curve analysis: a technical note
P2860
Q33801777-64563C2A-5379-490B-A7CF-9D3E0ADB065EQ36237352-64C09FF1-96C5-4F13-83CB-EDD7773FE650Q36243268-1DD6BB8A-B1D3-41AA-B0AB-080544BCACD4Q37261771-7EF79E7F-2DB0-4F81-AF93-5B7C3B9E51E6Q37472724-43245B8B-3961-4F17-89A2-13C14821F191Q38626615-7CEA8F7F-6293-4918-A4E9-4F8BE1F3F02BQ38685409-FCB47E1B-AECB-4FC8-B225-49D73B0040A4Q38725994-11CC39BC-6C43-48D8-AC19-29718714C420Q38843229-BBF1EC34-12F3-4C3C-91E4-30255397509DQ38868964-341AFDFD-6928-49A7-8D4C-046EE63CCF01Q38881882-28004439-022A-4D17-84E6-1A69B07653CAQ39331903-7A9CF168-8E41-4559-B890-9E0822692689Q41870535-05FCC79F-8EDF-4B74-B2E3-144C7F495415Q45943977-0EDFD12A-27D5-4513-A819-0CCBF86B5861Q47094124-B4BB590A-588D-4A56-8A76-6CBFE93D9984Q47096109-E33D7008-CF82-4559-9F14-28F7D0030E5FQ47143647-398B1D3A-A2FE-44CE-B0B9-9439F6A86586Q47162951-C8F9020F-FE13-4B50-8F0F-19D10D64A3E7Q47240653-3E59451D-EE4D-47FD-8464-7D8C56F5B8AAQ47362526-D8AAE654-3A39-4EF4-9980-F560F34E1603Q47689171-C56C4499-A0E8-443F-A33D-D7E6A301630BQ47719258-612A1204-0CB1-4788-B156-9F0CFF25C37EQ48180316-EF07466A-914A-4699-9817-9A69EF28DD7BQ48330118-7C66D1AD-782D-42EA-B4B6-E105575DDC4CQ52588104-FEC69862-29A7-4B77-87EC-7BBAD44A9DEDQ52695031-F4BE39BF-17D1-482F-8288-84970EEFA8C6Q54996710-39B3A99F-002A-4F7A-8CB0-EEE9701E3555Q55489099-DE35747E-0F83-4156-9F98-1AAE895D3B02Q55500019-44E25604-C90A-4921-BD1A-4F6B7CDA94DAQ57748350-A0D48D2B-167E-4AF8-AE76-0836ABB5B455Q58709039-D5A0107F-F428-4765-85C2-3659340189B7Q58804823-9CD575CB-606F-4B84-93CF-4AFBA7D2B8F1
P2860
Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Net benefit approaches to the ...... markers, and diagnostic tests.
@ast
Net benefit approaches to the ...... markers, and diagnostic tests.
@en
type
label
Net benefit approaches to the ...... markers, and diagnostic tests.
@ast
Net benefit approaches to the ...... markers, and diagnostic tests.
@en
prefLabel
Net benefit approaches to the ...... markers, and diagnostic tests.
@ast
Net benefit approaches to the ...... markers, and diagnostic tests.
@en
P2093
P2860
P356
P1433
P1476
Net benefit approaches to the ...... markers, and diagnostic tests.
@en
P2093
Andrew J Vickers
Ben Van Calster
Ewout W Steyerberg
P2860
P356
10.1136/BMJ.I6
P407
P577
2016-01-25T00:00:00Z